Media stories about uniQure N.V. (NASDAQ:QURE) have trended somewhat positive on Saturday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. uniQure N.V. earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.0838423051688 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the media stories that may have effected Accern Sentiment’s rankings:

uniQure N.V. (NASDAQ:QURE) opened at 10.70 on Friday. uniQure N.V. has a one year low of $4.72 and a one year high of $10.94. The firm’s market cap is $273.49 million. The company has a 50 day moving average of $8.67 and a 200-day moving average of $6.79.

uniQure N.V. (NASDAQ:QURE) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.78) by ($0.05). The business had revenue of $4.94 million for the quarter, compared to analyst estimates of $2.92 million. uniQure N.V. had a negative return on equity of 131.27% and a negative net margin of 289.94%. On average, equities research analysts predict that uniQure N.V. will post ($3.06) earnings per share for the current year.

QURE has been the subject of a number of recent analyst reports. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $17.00 price target on shares of uniQure N.V. in a research report on Friday, June 30th. Chardan Capital set a $13.00 price target on shares of uniQure N.V. and gave the company a “buy” rating in a research report on Sunday, July 23rd. ValuEngine upgraded shares of uniQure N.V. from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. Finally, Zacks Investment Research upgraded shares of uniQure N.V. from a “sell” rating to a “hold” rating and set a $9.25 price target for the company in a research report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $12.45.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at

uniQure N.V. Company Profile

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

Insider Buying and Selling by Quarter for uniQure N.V. (NASDAQ:QURE)

Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.